Back to Newsroom

ZYMFENTRA® (infliximab-dyyb) coverage continues to increase through partnership with top 3 Pharmacy Benefit Managers (PBMs)


- Celltrion USA has expanded access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous (SC) infliximab, to a significant share of the U.S. market

- The availability of ZYMFENTRA will support greater patient access and choice while helping to drive greater affordability to patients and health care systems

JERSEY CITY, N.J., Oct. 31, 2024 - Celltrion USA announced today that, through continued partnership with key PBMs and health plans, the company has expanded access to ZYMFENTRA® (infliximab-dyyb), the first and only U.S. Food and Drug Administration (FDA)-approved subcutaneous infliximab. With these partnerships Celltrion has now secured comprehensive access across the US health care system.

 

ZYMFENTRA has attained access to a
significant share of the U.S. market, providing an increase in availability to
patients and prescribers. This achievement reflects unmet needs of patients,
providers and payers, as well as Celltrion USA's ability to deliver on our
strong heritage of supply, manufacturing and commitment to biologics.

 

"Our extensive engagement with PBMs
and health plans from the outset have led to the comprehensive expanded access
for ZYMFENTRA in a short time frame," said Thomas Nusbickel, Celltrion USA
Chief Commercial Officer (CCO). "This achievement underscores ZYMFENTRA's
unique and innovative therapeutic advantages, and we look forward to expanding
our outreach to deliver its treatment benefits to as many patients in the U.S.
as possible."

 

ZYMFENTRA was approved by the FDA in
October 2023 through the Biologics License Application (BLA) under the 351 (a)
pathway of the Public Health Service Act (a "stand-alone" BLA). 
ZYMFENTRA is the first FDA-approved subcutaneous infliximab for the treatment
of moderately to severely active ulcerative colitis and moderately to severely
active Crohn's disease.

 

About Celltrion USA

Celltrion USA is Celltrion's U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion currently has five biosimilars approved by the U.S. FDA: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), VEGZELMA® (bevacizumab-adcd), and YUFLYMA®(adalimumab-aaty) as well as a novel biologic ZYMFENTRA®. Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence, and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit: www.celltrionusa.com/.

 

About ZYMFENTRA® (infliximab-dyyb)[1]

ZYMFENTRA is a prescription medicine used
as an injection under the skin (subcutaneous injection) by adults for the
maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product given by intravenous infusion
(IV), moderately to severely active Crohn's disease following treatment
with an infliximab product given by intravenous infusion (IV). ZYMFENTRA blocks
the action of tumor necrosis factor-alpha (TNF-alpha), a protein that can be
overproduced in response to certain diseases and cause the immune system to
attack normal, healthy parts of the body.

ZYMFENTRA® (infliximab-dyyb)
was approved by the FDA through the Biologics License Application (BLA) under
the 351 (a) pathway of the Public Health Service Act (a "stand-alone"
BLA). ZYMFENTRA is considered a new biologic with a first-approved subcutaneous
administration form and thus will be under patent protection for its dosage
form by 2037 and for its route of administration by 2040.

 

Indication and Important Safety Information

ZYMFENTRA is a prescription medicine
indicated in adults for maintenance treatment of:

- Moderately to severely active Crohn's disease following treatment with an infliximab product administered intravenously.

- Moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously.

 

It is not known if ZYMFENTRA is safe and effective in
children under 18 years of age.

 

What is the most important information I should know
about ZYMFENTRA?

 

SERIOUS INFECTIONS

 

Patients treated with ZYMFENTRA are at increased risk for
developing serious infections involving various organ systems and sites that
may lead to hospitalization or death. Discontinue ZYMFENTRA if a patient
develops a serious infection or sepsis.

 

Reported infections include:


- Active tuberculosis (TB), including reactivation of latent TB. Patients frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before and during treatment with ZYMFENTRA. Treatment for latent infection should be initiated prior to treatment with ZYMFENTRA.

- Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients may present with disseminated, rather than localized, disease. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.

- Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with ZYMFENTRA should
be carefully considered prior to initiating therapy in patients with chronic or
recurrent infection. Closely monitor patients for the development of signs and
symptoms of infection during and after treatment with ZYMFENTRA, including the
possible development of TB in patients who tested negative for latent TB
infection prior to initiating therapy.

Risk of infection may be higher in
patients greater than 65 years of age, patients with comorbid conditions and/or
patients taking concomitant immunosuppressant therapy. In clinical trials,
other serious infections observed in patients treated with infliximab included
arthritis bacterial, pneumonia, and urinary tract infection.

 

MALIGNANCIES

Malignancies, some fatal, have been reported in children,
adolescents, and young adults treated with TNF blockers, including infliximab
products.

Approximately half of these cases were
lymphomas, including Hodgkin's and non-Hodgkin's lymphoma. The other cases
represented a variety of malignancies, including rare malignancies that are
usually associated with immunosuppression and malignancies that are not usually
observed in children and adolescents. The malignancies occurred after a median
of 30 months after the first dose of therapy. Most of the patients were
receiving concomitant immunosuppressants.

 

Post-marketing cases of hepatosplenic T-cell lymphoma, a
rare type of T-cell lymphoma, have been reported in patients treated with TNF
blockers, including infliximab products. These cases have had a very aggressive
disease course and have been fatal. The majority of reported cases have
occurred in patients with Crohn's disease or ulcerative colitis, and most were
in adolescent and young adult males. Almost all of these patients had received
treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF
blocker at or prior to diagnosis. Carefully assess the risks and benefits of
treatment with ZYMFENTRA, especially in these patient types.

 

In clinical trials of all TNF blockers,
more cases of malignancies were observed compared with controls and the
expected rate in the general population. In clinical trials of some TNF
blockers, including infliximab products, more cases of other malignancies were
observed compared with controls. As the potential role of TNF blocker therapy
in the development of malignancies is not known, caution should be exercised
when considering treatment of patients with a current or a past history of
malignancy.

Melanoma and Merkel cell carcinoma have
been reported in patients treated with TNF blocker therapy, including
infliximab products. Periodic skin examination is recommended for all patients,
particularly those with risk factors for skin cancer.

 

CONTRAINDICATIONS

ZYMFENTRA is contraindicated in patients
with a previous severe hypersensitivity reaction to infliximab-dyyb, other
infliximab products, any of the inactive ingredients of ZYMFENTRA or any murine
proteins (severe hypersensitivity reactions have included anaphylaxis,
hypotension, and serum sickness).

 

HEPATITIS B VIRUS REACTIVATION

TNF blockers, including infliximab
products, have been associated with reactivation of hepatitis B virus (HBV) in
patients who are chronic carriers. Some cases were fatal. Patients should be
tested for HBV infection before initiating ZYMFENTRA. For patients who test
positive, consult a physician with expertise in the treatment of hepatitis B.
Exercise caution when prescribing ZYMFENTRA for patients identified as carriers
of HBV, and monitor closely for active HBV infection during and following
termination of therapy with ZYMFENTRA. Discontinue ZYMFENTRA in patients who
develop HBV reactivation and initiate antiviral therapy with appropriate
supportive treatment. Exercise caution when considering resumption of
ZYMFENTRA, and monitor patients closely.

 

HEPATOTOXICITY

Hepatobiliary disorders, including acute liver failure, jaundice abnormal hepatic function, hepatic steatosis, hepatitis, hepatotoxicity, hyperbilirubinemia, and non-alcoholic fatty liver, have been reported in patients receiving infliximab products post-marketing. Some cases were fatal or required liver transplant. Aminotransferase elevations were not noted prior to discovery of liver injury in many cases. Patients with symptoms or signs of liver dysfunction should be evaluated for evidence of liver injury. If jaundice and/or marked liver enzyme elevations (eg, ≥5 times the upper limit of normal) develop, ZYMFENTRA should be discontinued, and a thorough investigation of the abnormality should be undertaken.

 

CONGESTIVE HEART FAILURE

Cases of worsening congestive heart
failure (CHF) and new onset CHF have been reported with TNF blockers. Some
cases had a fatal outcome. In several exploratory trials of other TNF blockers
in the treatment of CHF, there were greater proportions of TNF-blocker-treated
patients who had CHF exacerbations requiring hospitalization or increased
mortality. ZYMFENTRA has not been studied in patients with a history of CHF and
ZYMFENTRA should be used with caution in patients with CHF.

 

HEMATOLOGIC REACTION

Cases of leukopenia, neutropenia,
thrombocytopenia, and pancytopenia (some fatal) have been reported. The causal
relationship to infliximab-product therapy remains unclear. Exercise caution in
patients who have ongoing or a history of significant hematologic abnormalities.
Advise patients to seek immediate medical attention if they develop signs and
symptoms of blood dyscrasias or infection. Consider discontinuation of
ZYMFENTRA in patients who develop significant hematologic abnormalities.

 

HYPERSENSITIVITY AND OTHER ADMINISTRATION REACTIONS

In post-marketing experience, serious
systemic hypersensitivity reactions (including anaphylaxis, hypotension, and
serum sickness) have been reported following administration of infliximab
products. If an anaphylactic or other clinically significant hypersensitivity
reaction occurs, institute appropriate therapy and discontinue ZYMFENTRA.

 

INJECTION SITE REACTIONS

In clinical studies, localized
injection-site reactions were reported following administration of ZYMFENTRA.
If a clinically significant injection-site reaction occurs, institute
appropriate therapy and discontinue ZYMFENTRA.

 

NEUROLOGIC REACTIONS

Agents that inhibit TNF have been
associated with central nervous system (CNS) manifestation of systemic
vasculitis, seizure, and new onset or exacerbation of CNS demyelinating
disorders, including multiple sclerosis and optic neuritis, and peripheral
demyelinating disorders, including Guillain-Barré syndrome. Exercise caution
when considering ZYMFENTRA in patients with these disorders and consider
discontinuation if these disorders develop.

 

RISK OF INFECTION WITH CONCURRENT ADMINISTRATION OF OTHER
BIOLOGICS PRODUCTS

Serious infections and neutropenia have
been reported with concurrent use of ZYMFENTRA with other immunosuppressive
biological products. The concurrent use of ZYMFENTRA with other
immunosuppressive biological products used to treat UC and CD may increase the
risk of infection and is not recommended.

 

RISK OF ADDITIVE IMMUNOSUPPRESSIVE EFFECTS FROM PRIOR
BIOLOGICAL PRODUCTS

Consider the half-life and mode of action
of prior biological products to avoid unintended additive immunosuppressive
effects when initiating ZYMFENTRA.

 

AUTOIMMUNITY

Treatment with TNF blockers may result in
the formation of autoantibodies and in the development of a lupus-like
syndrome. Discontinue ZYMFENTRA treatment if symptoms of a lupus-like syndrome
develop.

 

VACCINATIONS AND USE OF LIVE VACCINES/THERAPEUTIC
INFECTIOUS AGENTS

Prior to initiating ZYMFENTRA, update
vaccinations in accordance with current vaccination guidelines. Live vaccines
or therapeutic infectious agents should not be given with ZYMFENTRA due to the
possibility of clinical infections, including disseminated infections. At least
a 6-month waiting period following birth is recommended before the
administration of any live vaccine to infants exposed in utero to
ZYMFENTRA.

 

ADVERSE REACTIONS

In clinical trials with ZYMFENTRA, the most common adverse reactions occurring in ≥3% of ZYMFENTRA -treated patients included site reactions, COVID-19, anemia, arthralgia, infection site reaction, increased alanine aminotransferase and abdominal pain for UC, and COVID-19, headache, upper respiratory tract infection, injection site reaction, diarrhea, increased blood creatine phosphokinase, arthralgia, increased alanine aminotransferase, hypertension, urinary tract infection, neutropenia, dizziness and leukopenia for CD.

 

Please click for Full U.S.
Prescribing Information.

Globally, prescribing information varies; refer to the
individual country product label for complete information.

[1] Zymfentra
Prescribing Information